Loading...
A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder
Objectives: In a previous pivotal study of children and adolescents (aged 6–17 years) with attention-deficit/hyperactivity disorder (ADHD), dose-optimized SHP465 mixed amphetamine salts (MAS) extended-release (12.5–25 mg once daily) was superior to placebo in reducing ADHD symptoms. This study evalu...
Na minha lista:
| Udgivet i: | J Child Adolesc Psychopharmacol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Mary Ann Liebert, Inc., publishers
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7698843/ https://ncbi.nlm.nih.gov/pubmed/33185468 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cap.2020.0005 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|